Ilanit Boyango

937 total citations
16 papers, 582 citations indexed

About

Ilanit Boyango is a scholar working on Molecular Biology, Cell Biology and Cancer Research. According to data from OpenAlex, Ilanit Boyango has authored 16 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Cell Biology and 3 papers in Cancer Research. Recurrent topics in Ilanit Boyango's work include Proteoglycans and glycosaminoglycans research (13 papers), Fibroblast Growth Factor Research (10 papers) and Glycosylation and Glycoproteins Research (8 papers). Ilanit Boyango is often cited by papers focused on Proteoglycans and glycosaminoglycans research (13 papers), Fibroblast Growth Factor Research (10 papers) and Glycosylation and Glycoproteins Research (8 papers). Ilanit Boyango collaborates with scholars based in Israel, United States and Australia. Ilanit Boyango's co-authors include Israël Vlodavsky, Neta Ilan, Inna Naroditsky, Ralph D. Sanderson, Lilach Gutter-Kapon, Michael Elkin, Preeti Singh, Edward Hammond, Uri Barash and Ilana Doweck and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Cell Death and Disease.

In The Last Decade

Ilanit Boyango

15 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ilanit Boyango Israel	11	417	407	86	84	54	16	582
Lilach Gutter-Kapon Israel	6	240 0.6×	305 0.7×	54 0.6×	139 1.7×	23 0.4×	6	477
Evgeny Edovitsky Israel	7	591 1.4×	569 1.4×	110 1.3×	80 1.0×	65 1.2×	7	736
Lauren B. Tolliver United States	8	187 0.4×	350 0.9×	56 0.7×	152 1.8×	13 0.2×	8	484
Péter Hollósi Hungary	9	112 0.3×	221 0.5×	118 1.4×	106 1.3×	8 0.1×	17	407
Kei Matsuda United States	7	226 0.5×	478 1.2×	148 1.7×	305 3.6×	11 0.2×	13	687
Urvashi V. Roongta United States	4	164 0.4×	261 0.6×	201 2.3×	47 0.6×	8 0.1×	5	490
Shiro Kohi Japan	15	260 0.6×	406 1.0×	166 1.9×	403 4.8×	12 0.2×	35	743
Arulselvi Anbalagan United States	8	74 0.2×	222 0.5×	175 2.0×	203 2.4×	12 0.2×	10	486
Veli-Matti Kosma Finland	6	112 0.3×	172 0.4×	79 0.9×	109 1.3×	15 0.3×	8	411
Floortje L. Kessler Netherlands	11	119 0.3×	214 0.5×	77 0.9×	120 1.4×	11 0.2×	19	512

Countries citing papers authored by Ilanit Boyango

Since Specialization

Citations

This map shows the geographic impact of Ilanit Boyango's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilanit Boyango with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilanit Boyango more than expected).

Fields of papers citing papers by Ilanit Boyango

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilanit Boyango. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilanit Boyango. The network helps show where Ilanit Boyango may publish in the future.

Co-authorship network of co-authors of Ilanit Boyango

This figure shows the co-authorship network connecting the top 25 collaborators of Ilanit Boyango. A scholar is included among the top collaborators of Ilanit Boyango based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilanit Boyango. Ilanit Boyango is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Boyango, Ilanit, et al.. (2025). The immunophenotype of immune checkpoint-induced bullous pemphigoid: a cohort study. Cancer Immunology Immunotherapy. 74(12). 360–360.

Naroditsky, Inna, Sari Feld, Ilanit Boyango, et al.. (2024). Nuclear localization of heparanase 2 (Hpa2) attenuates breast carcinoma growth and metastasis. Cell Death and Disease. 15(3). 232–232. 4 indexed citations

Boyango, Ilanit, Aya Amitai-Lange, Neta Ilan, et al.. (2024). miR-184 represses β-catenin and behaves as a skin tumor suppressor. Cell Death and Disease. 15(2). 174–174. 3 indexed citations

Boer, Casper de, Zachary Armstrong, Uri Barash, et al.. (2022). Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo. Proceedings of the National Academy of Sciences. 119(31). e2203167119–e2203167119. 27 indexed citations

Barash, Uri, Shobith Rangappa, Chakrabhavi Dhananjaya Mohan, et al.. (2021). New Heparanase-Inhibiting Triazolo-Thiadiazoles Attenuate Primary Tumor Growth and Metastasis. Cancers. 13(12). 2959–2959. 15 indexed citations

Kessler, Ofra, Uri Barash, Ilanit Boyango, et al.. (2021). Heparanase 2 (Hpa2) attenuates tumor growth by inducing Sox2 expression. Matrix Biology. 99. 58–71. 15 indexed citations

Hantisteanu, Shay, et al.. (2021). The expression of heparanase in term and preterm human placentas. The Journal of Maternal-Fetal & Neonatal Medicine. 35(25). 5840–5845. 2 indexed citations

Ilan, Neta, et al.. (2020). Heparanase-The Message Comes in Different Flavors. Advances in experimental medicine and biology. 1221. 253–283. 21 indexed citations

Bhattacharya, Udayan, Lilach Gutter-Kapon, Ilanit Boyango, et al.. (2019). Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth. Cancer Research. 80(1). 57–68. 38 indexed citations

10.

Katz, Amit, Uri Barash, Ilanit Boyango, et al.. (2018). Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer. Oncotarget. 9(27). 19294–19306. 9 indexed citations

11.

Boyango, Ilanit, Uri Barash, Liat Fux, et al.. (2017). Targeting heparanase to the mammary epithelium enhances mammary gland development and promotes tumor growth and metastasis. Matrix Biology. 65. 91–103. 32 indexed citations

12.

Vornicova, Olga, Inna Naroditsky, Ilanit Boyango, et al.. (2017). Prognostic significance of heparanase expression in primary and metastatic breast carcinoma. Oncotarget. 9(5). 6238–6244. 17 indexed citations

13.

Vlodavsky, Israël, Preeti Singh, Ilanit Boyango, et al.. (2016). Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug Resistance Updates. 29. 54–75. 183 indexed citations

14.

Vornicova, Olga, Ilanit Boyango, Sari Feld, et al.. (2016). The prognostic significance of heparanase expression in metastatic melanoma. Oncotarget. 7(46). 74678–74685. 25 indexed citations

15.

Shteingauz, Anna, Ilanit Boyango, Inna Naroditsky, et al.. (2015). Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Research. 75(18). 3946–3957. 130 indexed citations

16.

Boyango, Ilanit, Uri Barash, Inna Naroditsky, et al.. (2014). Heparanase Cooperates with Ras to Drive Breast and Skin Tumorigenesis. Cancer Research. 74(16). 4504–4514. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact